Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Aïda Amer/Axios
Congress isn't feeling much urgency to help the fledgling market for biosimilars.
Why it matters: Advocates say that they need lawmakers' help soon, or else drugmakers will see biosimilars as a lost cause and the system will lose its only check on the cost of biologics.
Where it stands: Congress' ideas to enhance competition among traditional generics wouldn't do much for biosimilars — less than a dozen of which are on the market.
- “Different things need to be done for biosimilars because it’s a new industry," said Juliana Reed, president of the Biosimilars Forum.
- Lawmakers "don’t seem to appreciate" how many of the drugs have been stymied by intellectual property challenges or backwards commercial incentives, said Chip Davis, president and CEO of the Association for Accessible Medicines.
What they're saying: Both groups want Congress to alter Medicare's financial incentives to help bolster biosimilars. Davis' group also wants it to speed up patent lawsuits.
The other side: "It’s unclear that anything actually needs to be done on biosimilars as the law is still in its nascent stages," said a senior GOP aide working on drug prices.
Where it stands: The Senate health committee recently proposed accelerating the biosimilar approval process. Sens. John Barrasso and Sherrod Brown also said they'll have bills coming soon.
Yes, but: "I guess the answer ought to be yes. But I don’t know all of the issues yet," Finance Committee Chairman Chuck Grassley said when asked about increasing biosimilar competition.
Go deeper: How cheaper drugs are kept off the market